RHHBY Roche Holding Ltd ADR (Sponsored)

36.21
+0.19  (+1%)
Previous Close 36.02
Open 36.23
Price To Book 8.81
Market Cap 247,983,826,086
Shares 6,848,490,088
Volume 1,090,808
Short Ratio
Av. Daily Volume 1,568,057
Stock charts supplied by TradingView

NewsSee all news

  1. Phase III PEMPHIX study shows Roche's MabThera/Rituxan (rituximab) superior to mycophenolate mofetil in patients with pemphigus vulgaris

    40% of patients with pemphigus vulgaris (PV) achieved sustained complete remission, without the use of steroids for 16 weeks or more, when treated with MabThera/Rituxan compared to 9.5% of patients on mycophenolate

  2. Roche Partners with iHeartMedia to Present 'iHeartCountry One Night For Our Military' Concert to Bring Further Awareness of The Impact Diabetes Has On The Nation's Veteran Population

    INDIANAPOLIS, Oct. 14, 2019 /PRNewswire/ -- Roche ((SIX: RO, ROG, OTCQX:RHHBY) today announced that it has again partnered with iHeartMedia, the number one audio company in the United States, to present the iHeartCountry

  3. Phase III PEMPHIX study shows Roche's MabThera/Rituxan (rituximab) superior to mycophenolate mofetil in patients with pemphigus vulgaris

    40% of patients with pemphigus vulgaris (PV) achieved sustained complete remission, without the use of steroids for 16 weeks or more, when treated with MabThera/Rituxan compared to 9.5% of patients on mycophenolate

  4. Roche presents positive Phase III results for Tecentriq® (atezolizumab) in combination with platinum-based chemotherapy in people with previously untreated advanced bladder cancer

    IMvigor130 is the first positive Phase III study of a cancer immunotherapy combination in people with previously untreated advanced bladder cancer Tecentriq combination reduced the risk of disease worsening or death

  5. Roche and Spark Therapeutics, Inc. announce extension of tender offer for shares of Spark Therapeutics, Inc.

    Roche ((SIX: RO, ROG, OTCQX:RHHBY) and Spark Therapeutics, Inc. (NASDAQ:ONCE) (“Spark”) today announced that Roche has extended the offering period of its previously announced tender offer to purchase all

Drug Information

Drug catalyst information is displayed when you hover over / tap on the stage bar graph.

Phase 2 interim analysis is still pending - noted October 3, 2019. Enrolment to be completed November 2019. Final data due 1Q 2020 as per CC October 3, 2019.
Mytesi (crofelemer) HALT-D
Cancer related diarrhea (CRD)
Phase 3 data did not meet primary endpoint - June 20, 2019.
IMspire170 - cobimetinib and atezolizumab
First-line BRAF wild-type metastatic or unresectable locally advanced melanoma
First patient enrolled in Phase 3 trial announced January 28, 2019.
IONIS-HTT Rx
Huntington's Disease
Phase 3 data released May 10, 2018. Primary endpoint not met.
IMblaze370 - cobimetinib and atezolizumab
Third-line advanced or metastatic colorectal cancer
Phase 3 trial terminated following interim analysis indicating primary endpoint would not be met.
Crenezumab - CREAD 2
Alzheimer’s disease
Primary endpoint was met March 2, 2017. Data released June 5, 2017 - HR 0.81. Disease-free-survival +0.9% over Herceptin.
Perjeta + Herceptin (APHINITY)
Adjuvant HER2+ breast cancer
Approval announced June 11, 2018.
Venclexta (MURANO)
Relapsed or refractory Chronic Lymphocytic Leukemia (CLL)
Phase 3 data due 2H 2019.
RG7916 - SUNFISH
Spinal Muscular Atrophy (SMA)
Phase 3 trial terminated following interim analysis indicating primary endpoint would not be met.
Crenezumab - CREAD 1
Alzheimer’s disease
Phase 3 data due in 2020.
Kadcyla (KAITLIN)
HER2-positive breast cancer - adjuvant use
FDA approval announced May 6, 2019.
Kadcyla (KATHERINE)
HER2-positive breast cancer - residual invasive disease
FDA approval announced August 15, 2019.
Entrectinib
Solid tumors and ROS1-positive non-small cell lung cancer (NSCLC)
Phase 3 PFS endpoint met - PFS=6.3 vs. 5.6 months for chemo. HR 0.71.
Tecentriq+cb+pac/nab-pac - IMpower131
Squamous non-small cell lung cancer (NSCLC)
FDA Approval announced December 6, 2018.
Tecentriq + Avastin - IMpower150
Non-squamous non-small cell lung cancer (NSCLC)
PFS endpoint met. HR 0.74 - February 6, 2018.
TECENTRIQ (atezolizumab) - IMmotion151
Kidney cancer - renal cell carcinoma (mRCC)
Approval announced June 7, 2018.
MabThera/ Rituxan (rituximab)
Pemphigus vulgaris
Phase 3 data released July 19, 2018. PFS endpoint met, OS endpoint not yet met - final OS data due 2019.
TECENTRIQ (atezolizumab) plus chemotherapy (carboplatin and Abraxane) - IMpower132
Squamous non-small cell lung cancer (NSCLC)
FDA approval announced March 18, 2019.
Tecentriq+cb+etoposide - IMpower133
Squamous non-small cell lung cancer (NSCLC)
PDUFA date for sBLA extended by three months to December 2, 2019.
TECENTRIQ (atezolizumab) plus chemotherapy (carboplatin and Abraxane) - IMpower130
Squamous non-small cell lung cancer (NSCLC)
Phase 3 data due 2H 2019.
IMspire150 - cobimetinib, atezolizumab and vemurafenib - TRILOGY
BRAF V600 mutation-positive metastatic or unresectable locally advanced melanoma
FDA Approval announced October 4, 2018.
Hemlibra
Hemophilia
Phase 3 updated data at ESMO noted HR 0.43. PFS 34.8 months vs 10.9 months for crizotinib.
Alecensa - ALEX
Anaplastic lymphoma kinase (ALK)-positive metastatic (advanced) non-small cell lung cancer (NSCLC)
Phase 1b additional four cohorts added - noted July 15, 2019.
Cabozantinib + atezolizumab (TECENTRIQ) COSMIC-021
Solid tumors
FDA approval announced June 13, 2018.
Avastin (bevacizumab) + chemo
Ovarian cancer
Phase 3 enrollment has commenced - noted June 14, 2018.
Gantenerumab
Early Alzheimer's disease
FDA Approval announced October 24, 2018.
Baloxavir marboxil
Influenza
Phase 3 trial initiation announced July 26, 2018.
Subcutaneous Pertuzumab And Trastuzumab
HER2-positive early breast cancer
FDA approval announced November 21, 2018.
Venclexta
First line unfit AML
FDA approval announced May 15, 2019.
Venetoclax and obinutuzumab
Chronic Lymphocytic Leukemia
FDA Approval announced March 8, 2019.
TECENTRIQ (atezolizumab) plus Abraxane
Triple-negative breast cancer
Phase 3 interim analysis passed.
Tecentriq + chemo - IMpassion 031
Neoadjuvant triple negative breast cancer
Phase 3 data due 2H 2019.
Tecentriq + Avastin - IMbrave 150
Hepatocellular carcinoma
Phase 3 data presented at ASCO June 4, 2019. HR 0.35. CRR 49.5%. ORR 84.7% vs. 71.3%.
Venclexta plus Gazyva
Chronic lymphocytic leukemia (CLL)
Phase 3 data due 2H 2019.
Venclexta MIRROS
Acute myeloid leukemia (AML)
Phase 3 primary endpoint met.
Venclexta BELLINI
Multiple myeloma
FDA approval announced June 10, 2019.
Polatuzumab vedotin and bendamustine plus Rituxan (rituximab)
Diffuse large B-cell lymphoma (DLBCL)
PDUFA date for sNDA November 4, 2019.
Baloxavir marboxil
Influenza
Phase 3 OS update at ASCO June 4, 2019 - median OS=21.0 vs 18.7 months; HR=0.86.
Tecentriq plus nab-paclitaxel - IMpassion 130
Triple-negative breast cancer
Phase 3 data due 4Q 2019.
Idasanutlin (RG7388) - MIRROS
Acute myeloid leukemia (AML)
Phase 3 trials met primary endpoints - June 3, 2019.
Xolair (omalizumab)
Chronic rhinosinusitis with nasal polyps (CRSwNP)
FDA Approval announced September 27, 2019.
MabThera/ Rituxan (rituximab)
Granulomatosis with polyangiitis (GPA) / microscopic polyangiitis (MPA)
Phase 3 trial met primary and secondary endpoints - June 13, 2019.
Mabthera/Rituxan (rituximab) - PEMPHIX
Pemphigus vulgaris
Phase 3 data due 2020.
Ranibizumab
Neovascular Age-Related Macular Degeneration
Phase 3 data due 2020.
Tecentriq - IMvigor010
Urothelial cancer
Phase 3 PFS co-primary endpoint met - August 5, 2019.
Tecentriq (atezolizumab) plus chemotherapy
Urothelial carcinoma
FDA approval announced August 15, 2019.
Entrectinib
Solid tumors - NTRK gene fusion
Phase 3 data released September 12, 2019 noted HR 0.45.
Satralizumab
Neuromyelitis optica spectrum disorder (NMOSD)
Phase 3 trial met primary endpoint - September 12, 2019.
Tecentriq - IMpower110
Non-small cell lung cancer (NSCLC)
Phase 3 data at ESMO 2019 noted median PFS=8.2 versus 6.3 months; hazard ratio (HR)=0.82.
Tecentriq IMvigor130
Urothelial carcinoma

Latest News

  1. Phase III PEMPHIX study shows Roche's MabThera/Rituxan (rituximab) superior to mycophenolate mofetil in patients with pemphigus vulgaris

    40% of patients with pemphigus vulgaris (PV) achieved sustained complete remission, without the use of steroids for 16 weeks or more, when treated with MabThera/Rituxan compared to 9.5% of patients on mycophenolate

  2. Roche Partners with iHeartMedia to Present 'iHeartCountry One Night For Our Military' Concert to Bring Further Awareness of The Impact Diabetes Has On The Nation's Veteran Population

    INDIANAPOLIS, Oct. 14, 2019 /PRNewswire/ -- Roche ((SIX: RO, ROG, OTCQX:RHHBY) today announced that it has again partnered with iHeartMedia, the number one audio company in the United States, to present the iHeartCountry

  3. Phase III PEMPHIX study shows Roche's MabThera/Rituxan (rituximab) superior to mycophenolate mofetil in patients with pemphigus vulgaris

    40% of patients with pemphigus vulgaris (PV) achieved sustained complete remission, without the use of steroids for 16 weeks or more, when treated with MabThera/Rituxan compared to 9.5% of patients on mycophenolate

  4. Roche presents positive Phase III results for Tecentriq® (atezolizumab) in combination with platinum-based chemotherapy in people with previously untreated advanced bladder cancer

    IMvigor130 is the first positive Phase III study of a cancer immunotherapy combination in people with previously untreated advanced bladder cancer Tecentriq combination reduced the risk of disease worsening or death

  5. Roche and Spark Therapeutics, Inc. announce extension of tender offer for shares of Spark Therapeutics, Inc.

    Roche ((SIX: RO, ROG, OTCQX:RHHBY) and Spark Therapeutics, Inc. (NASDAQ:ONCE) (“Spark”) today announced that Roche has extended the offering period of its previously announced tender offer to purchase all

  6. Roche to present results of first prospective trial using blood-based next generation sequencing which successfully identifies people for treatment with Alecensa

    Efficacy of Alecensa® (alectinib) in people identified to have ALK-positive non-small cell lung cancer using liquid biopsy is consistent with efficacy in those identified by tissue analysis in the pivotal Phase III ALEX

  7. Genentech to Present Results of First Prospective Trial Using Blood-based Next Generation Sequencing Which Successfully Identifies People for Treatment With Alecensa (Alectinib)

    – Efficacy of Alecensa in people identified to have ALK-positive non-small cell lung cancer using liquid biopsy is consistent with efficacy in those identified by tissue analysis in the pivotal Phase III ALEX study

  8. FDA approves Roche's Rituxan (rituximab) in children with two rare blood vessel disorders

    Rituxan is the first and only FDA-approved treatment for paediatric patients 2 years of age and older living with granulomatosis with polyangiitis or microscopic polyangiitisThese two forms of vasculitis in children are

  9. Roche and Spark Therapeutics, Inc. announce extension of tender offer for shares of Spark Therapeutics, Inc.

    Basel, 30 September 2019  - Roche ((SIX: RO, ROG, OTCQX:RHHBY) and Spark Therapeutics, Inc. (NASDAQ:ONCE) ("Spark") today announced that Roche has extended the offering period of its previously announced tender offer to

  10. Roche to present new and updated data at ESMO 2019 reinforcing the use of Alecensa in the first-line setting for advanced ALK-positive non-small cell lung cancer

    New real-world data from the Flatiron database supports clinical benefits of Alecensa® (alectinib) across time to treatment discontinuation, real-world progression free survival and overall survival Final PFS and updated

  11. FDA Approves Genentech's Rituxan (rituximab) in Children With Two Rare Blood Vessel Disorders

    —Rituxan is the first and only FDA-approved treatment for pediatric patients 2 years of age and older living with granulomatosis with polyangiitis or microscopic polyangiitis— —These two forms of vasculitis in

  12. Roche's Tecentriq improves overall survival as a first-line monotherapy in certain people with advanced non-small cell lung cancer

    Phase III IMpower110 study showed Tecentriq monotherapy helped people with advanced non-small cell lung cancer (NSCLC) with high PD-L1 expression live longer compared with chemotherapy aloneData will be shared with

  13. Genentech's Tecentriq (Atezolizumab) Improves Overall Survival as a First-line Monotherapy in Certain People With Advanced Non-small Cell Lung Cancer

    – Phase III IMpower110 study showed Tecentriq monotherapy helped people with advanced non-small cell lung cancer (NSCLC) with high PD-L1 expression live longer compared with chemotherapy alone – – Data will be shared

  14. Roche's Tecentriq in combination with Avastin shows encouraging results in Phase Ib study of people with unresectable hepatocellular carcinoma

    The study showed a confirmed objective response rate of 36% for people treated with the Tecentriq and Avastin combination in unresectable hepatocellular carcinoma who have not received prior systemic therapyThe

  15. Gene Therapies with Potential to Conquer Tough-to-Tackle Breast Cancers

    NetworkNewsWire Editorial Coverage: Advances in biotechnology look to deliver promising new treatment options against breast cancer. Independent researchers have found that Genprex Inc.'s (NASDAQ:GNPX) (GNPX Profile)

  16. Gene Therapies with Potential to Conquer Tough-to-Tackle Breast Cancers

    NEW YORK, Sept. 24, 2019 /PRNewswire/ -- Advances in biotechnology look to deliver promising new treatment options against breast cancer.  Independent researchers have found that Genprex Inc.'s (NASDAQ:GNPX) (GNPX

  17. Roche to present new data from its broad oncology portfolio at the European Society for Medical Oncology 2019 Congress

    First positive results from a Phase III cancer immunotherapy combination study in people with previously untreated advanced bladder cancerFirst results from the BFAST study testing Foundation Medicine's FoundationOne®

  18. FDA approves cobas Babesia, Roche's first whole blood test for donor screening

    Roche is dedicated to helping save patients' lives by delivering state-of-the-art solutions to aid in the protection of the global blood supply from infectious diseasesIf undetected, Babesia infection can be fatal in

  19. Roche renews its commitment to the primary healthcare Phelophepa trains, marking the 25th anniversary

    Roche and Transnet, the main freight logistics company in South Africa, came together in 1994 to establish Phelophepa, the world's first comprehensive primary healthcare facility on railPhelophepa has touched the lives

  20. FDA grants Breakthrough Therapy Designation for Roche's Gazyva (obinutuzumab) in Lupus Nephritis

    There are currently no U.S. FDA-approved medicines for lupus nephritis The designation is based on the results of the phase II NOBILITY study that showed Gazyva, in combination with standard of care, helped more people

  21. FDA Grants Breakthrough Therapy Designation for Genentech's Gazyva (Obinutuzumab) in Lupus Nephritis

    —There are currently no FDA-approved medicines for lupus nephritis— —The designation is based on the results of the Phase II NOBILITY study that showed Gazyva, in combination with standard of care, helped more people

  22. Roche ranked as one of the most sustainable healthcare companies in the Dow Jones Sustainability Indices for the eleventh year running

    Roche ranked second in the 2019 Dow Jones Sustainability IndicesThe ranking acknowledges Roche's commitment to sustainability as an integral part of its business strategyCompared to 2018 Roche significantly improved

  23. Genentech Presents New Six-year Ocrevus (Ocrelizumab) Data Which Showed That Earlier Initiation and Continuation of Treatment Reduced Disability Progression in Multiple Sclerosis

    – Post-hoc analysis from a Phase III open-label extension study showed a 42% reduction in the risk of PPMS patients needing a wheelchair after six and a half years of Ocrevus treatment compared with patients who started

  24. Roche presents new 6-year OCREVUS (ocrelizumab) data which showed that earlier initiation and continuation of treatment reduced disability progression in multiple sclerosis

    Post-hoc analysis from a Phase III open-label extension study showed a 42 percent reduction in the risk of PPMS patients needing a wheelchair after 6.5 years of OCREVUS treatment compared with patients who started

  25. Roche's fixed-dose subcutaneous combination of Perjeta and Herceptin showed non-inferiority when compared to intravenous formulations for people with HER2-positive breast cancer

    New fixed-dose combination is administered under the skin in just minutes, significantly reducing the time spent receiving treatmentData will be submitted to health authorities around the world, including the US Food and

  26. Genentech's Fixed Dose Subcutaneous Combination of Perjeta and Herceptin Showed Non-Inferiority When Compared to Intravenous Formulations for People With HER2-Positive Breast Cancer

    - New fixed-dose combination is administered under the skin in just minutes, significantly reducing the time spent receiving treatment - - Data will be submitted to health authorities around the world, including the

  27. Genentech's Satralizumab Significantly Reduced Relapse Risk in Second Positive Phase III Study for Neuromyelitis Optica Spectrum Disorder

    – Pivotal Phase III SAkuraStar study shows 55% reduction in the risk of relapse for satralizumab monotherapy versus placebo presented at ECTRIMS Congress 2019 – – 74% reduction in the risk of relapse for satralizumab

  28. Roche's satralizumab significantly reduced relapse risk in second positive phase III study for neuromyelitis optica spectrum

    Pivotal phase III SAkuraStar study shows 55% reduction in the risk of relapse for satralizumab monotherapy versus placebo presented at ECTRIMS congress 201974% reduction in the risk of relapse for satralizumab

  29. Roche's Tecentriq as a first-line monotherapy helped certain people with advanced non-small cell lung cancer live longer compared with chemotherapy

    Data will be shared with health authorities globally, including the US Food and Drug Administration (FDA) and European Medicines Agency (EMA)Bullet              Basel, 12 September 2019 – Roche ((SIX: RO, ROG,

  30. Genentech's Tecentriq (Atezolizumab) as a First-Line Monotherapy Helped Certain People With Advanced Non-Small Cell Lung Cancer Live Longer Compared With Chemotherapy

    – Data will be shared with health authorities globally, including the U.S. Food and Drug Administration (FDA) and European Medicines Agency (EMA) – Genentech, a member of the Roche Group ((SIX: RO, ROG, OTCQX:RHHBY),

  31. Roche presents new OCREVUS (ocrelizumab) biomarker data that increase understanding of disease progression in multiple sclerosis at ECTRIMS

    Roche presents new OCREVUS (ocrelizumab) biomarker data that increase understanding of disease progression in multiple sclerosis at ECTRIMS Blood neurofilament light chain (NfL) levels were significantly lowered

  32. Genentech Presents New Ocrevus (Ocrelizumab) Biomarker Data That Increase Understanding of Disease Progression in Multiple Sclerosis at ECTRIMS

    – Blood neurofilament light chain (NfL) levels were significantly lowered following Ocrevus treatment in analyses of Phase III studies in RMS and PPMS – – New data show NfL may be a biomarker for predicting future

  33. European Commission approves Roche's new Tecentriq-based combination therapy as an initial treatment for most common form of advanced lung cancer

    The approval of the new Tecentriq-based combination expands treatment options for people across Europe affected by non-squamous non-small cell lung cancer (NSCLC)Decision based on data showing that the Tecentriq plus

  34. European Commission approves Roche's Tecentriq in combination with chemotherapy for the initial treatment of people with extensive-stage small cell lung cancer

    Tecentriq in combination with chemotherapy (carboplatin and etoposide) is the first and only cancer immunotherapy approved by the European Medicines Agency for the initial treatment of extensive-stage small cell lung

  35. Genentech to Present Pivotal Data for Satralizumab in Neuromyelitis Optica Spectrum Disorder and Six-year Ocrevus (Ocrelizumab) Data in Multiple Sclerosis at ECTRIMS

    – Investigational medicine satralizumab significantly reduces the risk of relapse in pivotal SAkuraStar monotherapy study for neuromyelitis optica spectrum disorder (NMOSD) – – New data provide insights into

  36. Genentech to Present Pivotal Data for Satralizumab in Neuromyelitis Optica Spectrum Disorder and Six-year Ocrevus (Ocrelizumab) Data in Multiple Sclerosis at ECTRIMS

    – Investigational medicine satralizumab significantly reduces the risk of relapse in pivotal SAkuraStar monotherapy study for neuromyelitis optica spectrum disorder (NMOSD) – – New data provide insights into

  37. Roche to present pivotal data for satralizumab in neuromyelitis optica spectrum disorder and six-year OCREVUS data in multiple sclerosis at ECTRIMS

    Investigational medicine satralizumab significantly reduces the risk of relapse in pivotal SAkuraStar monotherapy study for neuromyelitis optica spectrum disorder New data provide insights into neurofilament light chain

  38. Positive Phase III Results Show Xofluza (Baloxavir Marboxil) Reduces Risk of Developing the Flu After Contact With an Infected Person by 86 Percent

    – BLOCKSTONE study reaches primary endpoint of fewer people testing positive for the flu, with fever and at least one respiratory symptom, when treated with Xofluza versus placebo – – Xofluza may represent an

  39. Positive phase III results show Xofluza reduces risk of developing flu after contact with an infected person by 86%

    BLOCKSTONE study reaches primary endpoint of fewer people testing positive for flu, with fever and at least one respiratory symptom, when treated with Xofluza versus placeboXofluza may represent an important and

  40. Genentech Presents Positive Phase III Study Results for One-dose Xofluza (Baloxavir Marboxil) in Children With the Flu

    – Phase III MINISTONE-2 data are consistent with known safety profile of Xofluza in children and show comparable efficacy to oseltamivir – – Xofluza was administered as a one-dose oral suspension, a potentially more

  41. Roche presents positive phase III study results for one-dose Xofluza in children with flu

    Phase III MINISTONE-2 data are consistent with known safety profile of Xofluza (baloxavir marboxil) in children and show comparable efficacy to oseltamivir Xofluza was administered as a new one-dose oral suspension, a

  42. Roche launches VENTANA PD-L1 (SP142) Assay in CE markets as first companion diagnostic to identify triple-negative breast cancer patients eligible for treatment with Tecentriq

    This launch represents an important step in Roche's personalised healthcare strategy to fit treatments to patients who can benefit most from a specific medicineEach year 300,000 patients around the world are diagnosed

  43. European Commission approves Roche's Tecentriq in combination with Abraxane for people with PD-L1-positive, metastatic triple-negative breast cancer

    The Tecentriq combination marks the first cancer immunotherapy regimen to be available in Europe for triple-negative breast cancer – an aggressive and difficult-to-treat diseaseApproval based on the Phase III

  44. OncoMyx Therapeutics, Inc. to Be Honored With an AZBio Fast Lane Award

    The Arizona Bioindustry Association (AZBio) today announced that OncoMyx Therapeutics, Inc. has been named an AZBio Fast Lane Company and will be honored on October 2, 2019 at the AZBio Awards. The National Cancer